Loading
Erasca, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Casdin Alexander W., was filed 22 May 2024.
Erasca, Inc.: what insiders have been doing
Every trade that managers of Erasca, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The last twelve months, up to 19 October 2026, brought 10 filings signed by 4 insiders.
Only sales appear on the open market, 1 sale in all totalling €1.1M, filed by 1 insider. Garner Ebun filed the largest sale, €1.1M, on 3 April 2026.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Across the 5,810 companies tracked on its exchange, the median is 19 filings; at 10 filings, this issuer sits below that mark. Over the whole record (from 2021), the tally stands at 18 purchases and 2 sales.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
45
Thresholds
n/a
Buy Volume
€7M
18 ops. · all time
Sell Volume
€4M
2 ops. · all time
Who traded when
BuySaleEbun Garner1 sale
Since the insiders bought
- -61.0%Entry US$19.92 · Close at T+365 US$7.77
- -61.0%Entry US$19.92 · Close at T+365 US$7.77
- -61.0%Entry US$19.92 · Close at T+365 US$7.77
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$14.78
Analyst consensus
9 analysts1.60/5
US$20.00Target US$24.11(+63%)US$33.00
Income statement
EBITDA-US$128.3M
Net income-US$124.5M0.0% margin
Valuation
PER (forward)-23.7x
P/Book12.8x
Beta0.62
Balance sheet & cash
Market capUS$5.2B
Total debtUS$47.1M
Free Cash Flow-US$105.1M
Debt / Equity12%
Profitability & ownership
ROE-78.2%
ROA-21.4%
% insiders6.0%
% institutions86.2%
Last declaration on 15 October 2026
Declarations45 total
8,333 shares@ US$14.683CommonSEC144:0001628280-26-065966
8,333 shares@ US$15.97190.0027% mcap23.7% of flowCommonSEC144:0001628280-26-062070
8,333 shares@ US$18.2910.0031% mcap27.1% of flowCommonSEC144:0001628280-26-057296
8,333 shares@ US$18.91730.0032% mcap28.4% of flowCommonSEC144:0001628280-26-048993
8,333 shares@ US$14.09780.0020% mcap20.8% of flowCommonSEC144:0001628280-26-043327
80,000 shares@ US$1.709.0% of flowCommon StockSEC:0001193125-26-141395:0
80,000 shares@ US$16.4087.0% of flowCommon StockSEC:0001193125-26-141395:1
20,000 shares@ US$1.70100.0% of flowCommon StockSEC:0001193125-26-095181:0
17,793 shares@ US$1.194332.2% of flowCommon StockSEC:0001193125-26-030624:0
3,902 shares@ US$1.19430.3% of flowCommon StockSEC:0001193125-26-008076:0
6,200 shares0Common StockSEC:0000950170-25-080941:0
3,137 shares@ US$1.5648.1% of flowCommon StockSEC:0000950170-25-014197:0
5,715 shares@ US$1.5640.6% of flowCommon StockSEC:0000950170-25-014194:0
80,000 shares@ US$2.27447.1% of flowCommon StockSEC:0001209191-24-005689:0
Canonical exit: 19 Aug 2024 (T+90)
5,448 shares@ US$1.58950.6% of flowCommon StockSEC:0001209191-23-058910:0
7,478 shares@ US$1.589519.2% of flowCommon StockSEC:0001209191-23-058912:0
10,000 shares@ US$1.84819.5% of flowCommon StockSEC:0001209191-23-057833:0
Canonical exit: 5 Mar 2024 (T+90)
721,850 shares@ US$1.68728.3% of flowCommon StockSEC:0001209191-23-057681:0
Canonical exit: 4 Mar 2024 (T+90)
30,000 shares@ US$1.659512.9% of flowCommon StockSEC:0001209191-23-057297:0
Canonical exit: 3 Mar 2024 (T+90)
1,000,000 shares@ US$2.02648.4% of flowCommon StockSEC:0001209191-23-052403:0
Canonical exit: 3 Jan 2024 (T+90)
100,000 shares@ US$2.756.4% of flowCommon StockSEC:0001209191-23-035590:0
Canonical exit: 6 Sept 2023 (T+90)
20,000 shares@ US$2.761514.3% of flowCommon StockSEC:0001209191-23-023955:0
Canonical exit: 9 Jul 2023 (T+90)
100,000 shares@ US$2.846.6% of flowCommon StockSEC:0001209191-23-021458:0
Canonical exit: 26 Jun 2023 (T+90)
1,748 shares@ US$4.09711.7% of flowCommon StockSEC:0001209191-23-006481:0
2,388 shares@ US$4.0970.7% of flowCommon StockSEC:0001209191-23-006479:0
25 of 45 declarations
About Erasca, Inc.
Erasca, Inc. is a clinical-stage biopharmaceutical company listed on the US Nasdaq market (United States) and focused on precision oncology. Headquartered in San Diego, California, the company was co-founded in July 2018 with a mission to “erase cancer” by developing therapies that target cancers driven by the RAS/MAPK pathway. For French, Belgian, and Swiss investors, Erasca fits the profile of a high-R&D-intensity biotech where value creation depends primarily on clinical readouts, regulatory milestones, and the ability to fund development through successive proof-of-concept stages.
Erasca’s business model is built around a research and development platform aimed at multiple signaling nodes within the RAS/MAPK pathway, a biologically important driver in many solid tumors. The company describes its pipeline as deep and broad, with the aim of shutting down this pathway at virtually every turn. Its key programs include ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor. These assets are central to the company’s recent disclosures and represent the core of its investment thesis. Erasca does not yet have a commercial product, so its equity story remains tied to early-stage clinical data, scientific differentiation, and the likelihood that these programs can advance toward later-stage development.
Read moreShow less
From a competitive standpoint, Erasca operates in a crowded oncology innovation landscape populated by several companies pursuing RAS-pathway biology and targeted cancer therapeutics. Its differentiation lies in its concentrated strategic focus on the RAS/MAPK franchise and in the breadth of its pipeline across multiple signaling nodes. That specialization may support scientific optionality, but it also leaves the company exposed to execution risk typical of smaller biotechs, including dependence on a limited number of lead assets and on early clinical datasets that may still change materially as enrollment continues.
Recent company milestones have been important. In 2025, Erasca announced IND clearance and early advancement for its RAS-targeting franchise, including ERAS-4001. In 2026, the company reported positive preliminary phase 1 dose-escalation data for ERAS-0015 and outlined additional 2026-2027 milestones. Erasca also completed an upsized public equity offering in early 2026, underscoring the capital needs associated with clinical development. Overall, Erasca is best understood as a speculative but potentially differentiated precision-oncology biotech on the Nasdaq market in the United States, with future valuation likely to hinge on the quality, durability, and translatability of its clinical data.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
